Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Feb 07, 2013 9:28am
250 Views
Post# 20951258

RE: RE: RE: RE: Hemisphere GPS sells non-agricultu

RE: RE: RE: RE: Hemisphere GPS sells non-agricultu

Perhaps management wasn't involved in such discussions, but the board needed to make a decision befure undertaking the restructuring. RH and team would have had to compile a 3-5yr plan on where the see the company, its earnings potential, and growth potential and weigh that against what they could sell today. Boards often submit their 3-5yr plan to an investment bank to "assess" future value potential (i.e. if EPS, growth, margins etc etc are [X] then a theoretical future value is [Y]). That 3-5yr plan is based on managements assumptions and strategy. What strikes me is that the board probably never entertained the sale of the business today because of what they saw in terms of future value (based on the plan).

 

Regardless, I agree with you tthat Q1 is a critical quarter. Consistent growth, outperformance, and news flow (e.g. new OEM deals, significant product launches etc) are essential catalysts to drive the stock higher. It should be an exciting 2013. The brokers need to have a story to pitch clients, something that HEM has sorely lacked in the past few years. The bought deal was intended to be that catalyst a couple of years ago and that fell flat (deal fell through). Re-establishing that credibility (investors will hestitate on fool me once, but fool me twice?) will take some time. Good news is that once momentum gets going it could be huge. I hope you are right that more analysts will start covering the stock (would help with marketing).

 

Your statement "thinking we are worth more and being worth more are two different things". I couldn't agree more. That's why we invest at low prices today. :)

Bullboard Posts